文献速递白血病

慢性髓性白血病BCR-ABL1转录本定量聚合酶链反应评估:e14a2转录本患者预后改善是否为技术假象?

Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
PubMed 文献 · Br J Haematol · 2022-01-08

研究设计e14a2特异性定量PCR检测,与e13a2标准检测比较未发现结果差异,并证明商业e14a2标准品导致e13a2转录本显著高估;校正qPCR值后回顾患者管理,尽管qPCR结果有统计学显著差异,但对患者管理或结局无影响。

要点

  • e14a2特异性检测与e13a2标准检测结果无差异。
  • 商业e14a2标准品导致e13a2转录本显著高估。
  • 校正qPCR值后对患者管理或结局无影响。

核心结论

  • 尽管qPCR结果存在统计学显著差异,但对患者管理或结局无影响。
  • 至少在本机构,不宜对e13a2或e14a2患者分别进行检测。

研究设计与样本

  • 设计e14a2特异性定量PCR检测,与e13a2标准检测比较。
  • 回顾校正qPCR值后的患者管理。

主要发现

  • e14a2特异性检测与e13a2标准检测结果无差异。
  • 商业e14a2标准品导致e13a2转录本显著高估。

临床怎么用

  • 至少在本机构,不宜对e13a2或e14a2患者分别进行检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical outcome of chronic myeloid leukaemia patients has vastly improved since the introduction of tyrosine kinase inhibitor treatment, with a significant proportion of patients able to achieve treatment-free remission. However, studies have shown that patients with the e13a2 transcript were less likely to achieve major molecular response compared to those with e14a2 transcripts. Most quantitative polymerase chain reaction (PCR) assays for detection of the BCR-ABL1 fusion gene do not differentiate between the two transcripts and we therefore hypothesised that technical bias linked to the qPCR assay could partially explain the discrepancy in outcomes. We designed an e14a2-specific assay and identified no difference in results compared to an e13a2 standard assay. We then demonstrated that the commercial e14a2 standards were causing a significant overestimation of the e13a2 transcripts. Finally, we reviewed patient management after the qPCR values were corrected, using our new evaluation. We concluded that despite statistically significant differences in qPCR results, there was no impact on patient management or outcome. We conclude that, at least in our institution, it would be inappropriate to perform separate assays for patients with e13a2 or e14a2.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dominy KM, Claudiani S, O'Hare M, et al. Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology? Br J Haematol. 2022. PMID: 34997766. doi:10.1111/bjh.18026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。